SCHEMBL4741283

SCHEMBL4741283

O=C(NCc1ccccc1)c1cccc(-c2nc(O)cc(=O)n2Cc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 1/20 0.52
ROCK2 O75116 2/20 0.52
GRK2 P25098 2/20 0.52
EPHX2 P34913 1/20 0.50
NR1H4 Q96RI1 1/20 0.50
JAK2 O60674 1/20 0.49
MAP4K4 O95819 1/20 0.49
CHEK2 O96017 1/20 0.49
PRKCG P05129 1/20 0.49
CDK1 P06493 1/20 0.49
FES P07332 1/20 0.49
RET P07949 1/20 0.49
ROS1 P08922 1/20 0.49
FER P16591 1/20 0.49
FLT1 P17948 1/20 0.49
AXL P30530 1/20 0.49
FLT4 P35916 1/20 0.49
KDR P35968 1/20 0.49
FLT3 P36888 1/20 0.49
MAPK9 P45984 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4995678 0.87 SMN1; SMN2 (0.51) PPARGTP53
SCHEMBL4737051 0.81 BCL2 (0.55) MAPTTP53
SCHEMBL4994504 0.79 EGLN3 (0.57) CFDROCK2GRK2EPHX2NR1H4
SCHEMBL4737864 0.78 CFTR (0.53) HDAC8HDAC6MAPTTP53
Trifluoroacetic Acid SCHEMBL15569280 0.77 MAPT (0.57) CFDROCK2GRK2HDAC8HDAC6
SCHEMBL4784822 0.72 MEN1 (0.45) MAPT
SCHEMBL11900328 0.71 HDAC6 (0.87) CFDEPHX2NR1H4HDAC2HDAC8
SCHEMBL3031649 0.71 HDAC8 (0.85) CFDEPHX2NR1H4JAK2MAP4K4
SCHEMBL10084687 0.71 NPC1 (0.73) CFDEPHX2NR1H4HDAC2HDAC8
SCHEMBL4741826 0.71 CCR2 (0.43) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 CFD 2975/4885ROCK2 3739/4885GRK2 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.